Relapsed/Refractory Follicular Lymphoma
Conditions
Brief summary
To evaluate time from randomization to the first disease progression based on Lugano 2014 classification guidelines as assessed by Independent Review Adjudication committee (IRAC) or death from any cause, whichever occurs earlier.
Detailed description
To evaluate how long a participant lives overall., To evaluate how well the cancer responds to the treatment., To evaluate how long the cancer responds., To evaluate how long it takes for participants to start a new treatment., To evaluate how the treatment impacts the quality of life of participants while they are taking it.
Interventions
DRUGLENALIDOMIDE
DRUGGolcadomide
DRUGBENDAMUSTINE HYDROCHLORIDE
DRUGCYCLOPHOSPHAMIDE
DRUGPREDNISOLONE
DRUGVINCRISTINE SULFATE
DRUGPEGFILGRASTIM
DRUGPREDNISONE
DRUGDOXORUBICIN HYDROCHLORIDE
DRUGRITUXIMAB
Sponsors
Celgene Corp.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate time from randomization to the first disease progression based on Lugano 2014 classification guidelines as assessed by Independent Review Adjudication committee (IRAC) or death from any cause, whichever occurs earlier. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate how long a participant lives overall., To evaluate how well the cancer responds to the treatment., To evaluate how long the cancer responds., To evaluate how long it takes for participants to start a new treatment., To evaluate how the treatment impacts the quality of life of participants while they are taking it. | — |
Countries
Finland, France, Germany, Greece, Italy, Netherlands, Poland, Spain
Outcome results
None listed